INTERMITTENT VERSUS CONTINUOUS ANDROGEN B LOCKAGE

Androgenablation is the therapy of choice for the treatment of advance d and metastatic prostate cancer. However, in more than half of the pa tients the disease will ultimately progress within 2 years. Intermitte nt androgenablation through medical castration maintains the apoptotic potential. By periodically changing phases on and off treatment the q ualify of life of the patients is improved. Apart from reduced toxicit y treatment costs are lowered and tumor progression is possibly delaye d. In how far survival is influenced is presently not clear and remain s to be evaluated in further clinical trials.